Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
48
EHC Quote, Financials, Valuation and Earnings
Last price:
$106.34
Seasonality move
:
0.22%
Day range:
$106.04 - $107.78
52-week range:
$87.85 - $127.99
Dividend yield:
0.66%
P/E ratio:
20.10x
P/S ratio:
1.88x
P/B ratio:
4.51x
Volume:
872.8K
Avg. volume:
900.3K
1-year change:
14.93%
Market cap:
$10.7B
Revenue:
$5.4B
EPS (TTM):
$5.29
Analysts' Opinion
-
Consensus RatingEncompass Health Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $140.33, Encompass Health Corp. has an estimated upside of 32.22% from its current price of $106.14.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $125.00 representing 100% downside risk from its current price of $106.14.
Fair Value
-
According to the consensus of 11 analysts, Encompass Health Corp. has 32.22% upside to fair value with a price target of $140.33 per share.
EHC vs. S&P 500
-
Over the past 5 trading days, Encompass Health Corp. has overperformed the S&P 500 by 0.02% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Encompass Health Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Encompass Health Corp. has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Encompass Health Corp. reported revenues of $1.5B.
Earnings Growth
-
Encompass Health Corp. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Encompass Health Corp. reported earnings per share of $1.24.
Enterprise value:
14B
EV / Invested capital:
--
Price / LTM sales:
1.88x
EV / EBIT:
14.00x
EV / Revenue:
2.42x
PEG ratio (5yr expected):
0.72x
EV / Free cash flow:
34.84x
Price / Operating cash flow:
27.01x
Enterprise value / EBITDA:
10.61x
Gross Profit (TTM):
$1.2B
Return On Assets:
10.81%
Net Income Margin (TTM):
12.42%
Return On Equity:
24.34%
Return On Invested Capital:
12.69%
Operating Margin:
16.49%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.7B | $5.2B | $5.8B | $1.4B | $1.5B | |
| Gross Profit | $913M | $1B | $1.2B | $263.1M | $299.7M | |
| Operating Income | $721.6M | $822.1M | $1B | $209.1M | $243.6M | |
| EBITDA | $988.7M | $1.1B | $1.3B | $287.5M | $326M | |
| Diluted EPS | $3.50 | $4.14 | $5.29 | $1.06 | $1.24 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $909.8M | $733.8M | $813.7M | $933.9M | $869.8M | |
| Total Assets | $6.7B | $5.5B | $6B | $6.5B | $6.9B | |
| Current Liabilities | $793.9M | $604.7M | $639.2M | $897.4M | $762M | |
| Total Liabilities | $4.4B | $3.7B | $3.8B | $3.7B | $3.7B | |
| Total Equity | $2.3B | $1.7B | $2.2B | $2.7B | $3.2B | |
| Total Debt | $3.4B | $2.9B | $2.9B | $2.8B | $2.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $822M | $925M | $1.1B | $267.8M | $270.8M | |
| Cash From Investing | -$537.4M | -$504.4M | -$728.2M | -$55.1M | -$201.3M | |
| Cash From Financing | -$247.5M | -$362.9M | -$485.4M | -$195.9M | -$113.2M | |
| Free Cash Flow | $259.8M | $258.6M | $402.6M | $120.3M | $83.7M | |
EHC
Sector
Market Cap
$10.7B
$28.2M
Price % of 52-Week High
83.09%
50.98%
Dividend Yield
0.66%
0%
Shareholder Yield
1.68%
-1.55%
1-Year Price Total Return
14.93%
-17.58%
Beta (5-Year)
0.756
0.498
Dividend yield:
0.66%
Annualized payout:
$0.47
Payout ratio:
15.37%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$107.14
200-day SMA
Sell
Level
$115.58
Bollinger Bands (100)
Sell
Level
111.99 - 125.41
Chaikin Money Flow
Buy
Level
216.4M
20-day SMA
Sell
Level
$108.39
Relative Strength Index (RSI14)
Sell
Level
32.95
ADX Line
Sell
Level
37.53
Williams %R
Buy
Level
-88.4146
50-day SMA
Sell
Level
$113.75
MACD (12, 26)
Sell
Level
-1.94
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
161.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.9531)
Sell
CA Score
(Annual)
Level (-0.4606)
Buy
Beneish M-Score
(Annual)
Level (-2.7043)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.5068)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Encompass Health Corp. engages in the provision of post-acute healthcare services. It provides specialized rehabilitative treatment on an inpatient basis. The company was founded by Richard M. Scrushy on February 22, 1984 and is headquartered in Birmingham, AL.
Stock Forecast FAQ
In the current month, EHC has received 11 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EHC average analyst price target in the past 3 months is $140.33.
-
Where Will Encompass Health Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Encompass Health Corp. share price will rise to $140.33 per share over the next 12 months.
-
What Do Analysts Say About Encompass Health Corp.?
Analysts are divided on their view about Encompass Health Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Encompass Health Corp. is a Sell and believe this share price will drop from its current level to $125.00.
-
What Is Encompass Health Corp.'s Price Target?
The price target for Encompass Health Corp. over the next 1-year time period is forecast to be $140.33 according to 11 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EHC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Encompass Health Corp. is a Buy. 11 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EHC?
You can purchase shares of Encompass Health Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Encompass Health Corp. shares.
-
What Is The Encompass Health Corp. Share Price Today?
Encompass Health Corp. was last trading at $106.34 per share. This represents the most recent stock quote for Encompass Health Corp.. Yesterday, Encompass Health Corp. closed at $106.14 per share.
-
How To Buy Encompass Health Corp. Stock Online?
In order to purchase Encompass Health Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get EHC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EHC
Sector
P/E ratio
20.10x
24.09x
PEG ratio
0.72x
-0.01x
P/B ratio
4.51x
1.81x
Price / LTM sales
1.88x
1.59x
Growth Metrics
EHC
Sector
Revenue growth
9.36%
4.68%
Earnings growth
16.68%
11.06%
Revenue (5-year growth)
3.13%
6.45%
Earnings forecast
$1.30
-$0.18
Profitability
EHC
Sector
Profitability FY 2024
$1.1B
$3.6M
Return on invested capital
12.69%
-31.84%
Return on assets
10.81%
-28.18%
Return on equity
24.34%
-37.63%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
5
Estimated Next Earnings Date
Jan
28
Balance Sheet
EHC
Sector
Total cash
$127.8M
$26.3M
Short term investments
--
$26M
Total assets
$6.5B
$76.7M
Long term debt
$2.6B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
